Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 03:30 am EDT
Share
Amicogen, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 942.21 million compared to KRW 979 million a year ago. Net loss was KRW 11,114.87 million compared to net income of KRW 46,824.68 million a year ago. Basic loss per share from continuing operations was KRW 563 compared to basic earnings per share from continuing operations of KRW 2,436 a year ago. Diluted loss per share from continuing operations was KRW 563 compared to diluted earnings per share from continuing operations of KRW 2,432 a year ago. Basic loss per share was KRW 563 compared to basic earnings per share of KRW 2,436 a year ago.
For the six months, sales was KRW 1,753.77 million compared to KRW 2,300.74 million a year ago. Net loss was KRW 19,824.92 million compared to net income of KRW 44,979.75 million a year ago. Basic loss per share from continuing operations was KRW 1,004 compared to basic earnings per share from continuing operations of KRW 2,341 a year ago. Diluted loss per share from continuing operations was KRW 1,004 compared to diluted earnings per share from continuing operations of KRW 2,337 a year ago. Basic loss per share was KRW 1,004 compared to basic earnings per share of KRW 2,341 a year ago.
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
AMICOGEN, INC. 